{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:03:38Z","timestamp":1781953418248,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1136\/ijgc-2021-003053","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T11:50:13Z","timestamp":1639569013000},"page":"153-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evaluation of patterns of progression on poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer: a cross-sectional study"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6842-1424","authenticated-orcid":false,"given":"Victoria R","family":"Cerda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobbie Jo","family":"Rimel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Kamrava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2021-003053_bb0010","unstructured":"American Cancer Society . Key statistics for ovarian cancer. Available: https:\/\/www.cancer.org\/cancer\/ovarian-cancer\/about\/key-statistics.html [Accessed 20 Jul 2021]."},{"key":"10.1136\/ijgc-2021-003053_bb0015","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2021-003053_bb0020","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/AOG.0000000000003086","article-title":"Nomogram for predicting individual survival after recurrence of advanced-stage, high-grade ovarian carcinoma","volume":"133","author":"Rose","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2021-003053_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.950","article-title":"811MO maintenance olaparib for patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (Y) follow-up (f\/u) from SOLO1","volume":"31","author":"Banerjee","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1136\/ijgc-2021-003053_bb0030","unstructured":"H Slater . 5-year follow-up from phase 3 SOLO-1 continues to show long-term PFS with olaparib. Available: https:\/\/www.cancernetwork.com\/view\/5-year-follow-up-from-phase-3-solo-1-continues-to-show-long-term-pfs-with-olaparib [Accessed 20 Jul 2021]."},{"key":"10.1136\/ijgc-2021-003053_bb0035","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2021-003053_bb0040","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2021-003053_bb0045","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2021-003053_bb0050","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/IGC.0000000000001258","article-title":"Angiogenesis inhibitors for the treatment of ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Wang","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2021-003053_bb0055","doi-asserted-by":"crossref","DOI":"10.1186\/s40661-015-0020-3","article-title":"Immunotherapy in endometrial cancer - an evolving therapeutic paradigm","volume":"2","author":"Longoria","year":"2015","journal-title":"Gynecol Oncol Res Pract"},{"key":"10.1136\/ijgc-2021-003053_bb0060","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1136\/ijgc-2021-003053_bb0065","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.clon.2019.05.015","article-title":"The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively?","volume":"31","author":"Patel","year":"2019","journal-title":"Clin Oncol"},{"key":"10.1136\/ijgc-2021-003053_bb0070","unstructured":"National Comprehensive Cancer Network . Small cell lung cancer. Version (1.2022). Available: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sclc.pdf [Accessed Jan 2021]."},{"key":"10.1136\/ijgc-2021-003053_bb0075","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.26312","article-title":"Evaluation of definitive stereotactic body radiotherapy and outcomes in adults with extracranial oligometastasis","volume":"3","author":"Poon","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1136\/ijgc-2021-003053_bb0080","doi-asserted-by":"crossref","first-page":"P1325","DOI":"10.1016\/j.ijrobp.2021.09.014","article-title":"Consolidative use of radiotherapy to block (CURB) oligoprogression: interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic cancers of the lung and breast","volume":"111","author":"Tsai","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2021-003053_bb0085","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2021-003053_bb0090","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"JCO"},{"key":"10.1136\/ijgc-2021-003053_bb0095","article-title":"Stereotactic body radiotherapy for lymph node relapse in ovarian cancer","volume":"1","author":"Trippa","year":"2016","journal-title":"Clin Oncol"},{"key":"10.1136\/ijgc-2021-003053_bb0100","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ijrobp.2018.03.058","article-title":"Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday","volume":"101","author":"Lazzari","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2021-003053_bb0105","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1634\/theoncologist.2019-0309","article-title":"A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study): a collaboration of MITO, AIRO GYN, and MaNGO groups","volume":"25","author":"Macchia","year":"2020","journal-title":"Oncologist"},{"key":"10.1136\/ijgc-2021-003053_bb0110","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160251","article-title":"Stereotactic body radiotherapy for oligoprogressive cancer","volume":"89","author":"Cheung","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1136\/ijgc-2021-003053_bb0115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.radonc.2021.06.012","article-title":"Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: treatment indication matters","volume":"161","author":"Tan","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1136\/ijgc-2021-003053_bb0120","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-003053_bb0125","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2021-003053_bb0130","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-003053_bb0135","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/jamaoncol.2021.0687","article-title":"Evaluation of safety of stereotactic body radiotherapy for the treatment of patients with multiple metastases: findings from the NRG-BR001 phase 1 trial","volume":"7","author":"Chmura","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2021-003053_bb0140","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.radonc.2017.08.032","article-title":"Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial","volume":"126","author":"Trovo","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1136\/ijgc-2021-003053_bb0145","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-003053_bb0150","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2021-003053_bb0155","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat Rev Clin Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24005735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24005735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2021-003053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:39:33Z","timestamp":1753223973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24005735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1048891X24005735"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2021-003053","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of patterns of progression on poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer: a cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2021-003053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}